Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Methotrexate (MTX) Combined With Chemoimmunotherapy Plus Pirtobrutinib in Patients With Systemic Diffuse Large B-Cell Lymphoma (DLBCL) and Central Nervous System Involvement

NCT07812493 is registered in ClinicalTrials.gov with Pengpeng Xu as lead sponsor.

NCT NCT07812493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Methotrexate (MTX) Combined With Chemoimmunotherapy Plus Pirtobrutinib in Patients With Systemic Diffuse Large B-Cell Lymphoma (DLBCL) and Central Nervous System Involvement
Lead sponsor
Pengpeng Xu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2030
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns involvement of systemic lymphoma, dlbcl - diffuse large b cell lymphoma, immunochemotherapy, pirtobrutinib